<DOC>
	<DOC>NCT01358383</DOC>
	<brief_summary>This is an assessment of Pharmacokinetics of a single oral dose of VIMOVO in healthy adult volunteers.</brief_summary>
	<brief_title>Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers</brief_title>
	<detailed_description>A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of a Single Oral Dose of VIMOVO (250 mg Naproxen/20 mg Esomeprazole)in Healthy Adult Subjects</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Healthy male and female subjects aged 18 to 55 years Capable of understanding and complying with the Clinical Study Protocol Body mass index (BMI) of 19 to 30 kg/m2 and weight of 50 to 100 kg Previous enrollment in the present study Receipt of another investigational product within 4 weeks before this study or plans to participate in another study at the same time as this study Female subjects with a positive urine pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Juvenile Idiopathic Arthritis</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>VIMOVO</keyword>
	<keyword>fasting state</keyword>
	<keyword>Amount of VIMOVO in the blood</keyword>
	<keyword>taken on empty stomach</keyword>
</DOC>